Telemonitoring in heart failure

Telemonitoring in heart failure: a multicentre randomised trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN39223875

Enrollment

160

Registered

2010-02-09

Start date

2008-04-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congestive heart failure Circulatory System Heart failure

Interventions

Telemonitoring will consist of daily patient self-measurements of body weight, blood pressure and heart rate with devices that allow automatic transfer of registered data to a web-site. This web-site

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients hospitalised for decompensated heart failure, necessitating intravenous (IV) diuretics or augmentation of oral (PO) diuretic, IV inotropic or IV vasodilator. Patients should be stabilised with treatment including angiotensin converting enzyme (ACE) inhibitors (or angiotensin II receptor antagonists [AIIA]), betablockers and diuretics at discharge. 2. Patients should be capable of understanding the aims of the study and to use the telemonitoring system 3. Aged between 50 and 85 years, either sex

Exclusion criteria

Exclusion criteria: 1. Reversible forms of heart failure 2. Heart failure due to aortic stenosis 3. Isolated right heart failure 4. Patients residing in "elderly homes" 5. Severe renal disease (glomerular filtration rate [GFR] less than 20 ml/min), planned dialysis in the next 6 months 6. Planned implantation of biventricular pacemaker, or cardiac surgery 7. Life expectancy less than 1 year 8. Severe pulmonary disease

Design outcomes

Primary

Measure	Time frame
1. Number and duration of hospitalisation after the start of the study 2. Number of unplanned consultations with the heart failure team and GP 3. Number of phone calls (and amount of time spent) between the HF nurse and the patient 4. Quality of life (Minnesota Living with Heart Failure Questionnaire) 5. Mortality rate 6. Number of medication changes 7. Number of changes in alert limits Measured at entry of study, and after 6 months of follow-up.	—

Measure

Time frame

1. Number and duration of hospitalisation after the start of the study 2. Number of unplanned consultations with the heart failure team and GP 3. Number of phone calls (and amount of time spent) between the HF nurse and the patient 4. Quality of life (Minnesota Living with Heart Failure Questionnaire) 5. Mortality rate 6. Number of medication changes 7. Number of changes in alert limits Measured at entry of study, and after 6 months of follow-up.

—

Secondary

Measure	Time frame
Blood B-type natriuretic peptide (BNP) content, measured at entry of study, and after 6 months of follow-up.	—

Countries

Belgium

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026